Author(s)

Xiaoyan Wang

Corresponding Author

Xiaoyan Wang

ABSTRACT

Chronic migraine (CM) is a prevalent disease that induces neurological symptoms. CM burdens the life qualities of patients with comorbidities, including cardiovascular and psychiatric disorders. Monoclonal antibody Eptinezumab, targeting Calcitonin gene-related peptide (CGRP), is a prophylactic treatment for CM. The efficacy and safety of Eptinezumab are confirmed in 6 clinical studies, as 83.3% of patients reported improved life quality after 104 weeks. Other commonly used prophylactic drugs, incorporating antiepileptic drugs, beta-blockers, and triptans, have also established their efficacy and safety in clinical conditions. This paper analyses the efficacy and safety of Eptinezumab and compares it to other prophylactic drugs.

KEYWORDS

Eptinezumab, chronic migraine, calcitonin gene-related peptide (CGRP), sodium valproate, frovatriptan